Heyuan

People with end stage kidney disease ESKD who require dialysis face a much higher risk of cardiovascular disease compared to the general population, with cardiac issues causing 58% of deaths in this group. However, while aspirin is known to reduce cardiovascular problems in the general population, there is limited evidence about its effects in dialysis patients. The ASPIrin to Reduce Event in Dialysis ASPIRED trial aims to study whether taking low-dose aspirin can safely improve cardiovascular outcomes in people with ESKD receiving dialysis. This study is a multi-center, double-blind, randomized controlled trial that will compare daily low-dose aspirin 100 mg to a placebo pill in patients undergoing dialysis. The trial uses an existing dialysis registry platform to screen, recruit, and collect data during routine clinical care, minimizing participant burden and study costs. Randomization is managed through a secure web-based system, and follow-up visits occur every six months as part of regular clinic visits. The trial is expected to last approximately five years and includes oversight by an independent safety and monitoring board. Participants will be involved in regular six-monthly clinic visits where their health will be monitored as part of their usual dialysis care. Researchers will track the occurrence of major cardiovascular events, including heart attacks, strokes, vascular complications, and deaths, throughout the study period. Data will be collected from routine clinical procedures and the dialysis registry to evaluate outcomes. Safety and efficacy will be closely monitored, and the study will follow participants for up to five years to assess the long-term effects of aspirin use in this population.

Researchers are evaluating the safety and effectiveness of low-dose tenecteplase in elderly patients aged 70 and older who have experienced an acute ischemic stroke. This multicenter, randomized controlled trial focuses on treatment within 4.5 hours of stroke onset to assess how this therapy may improve neurological outcomes compared to a standard dose. Participants are randomly assigned to receive either a low dose 0.175 mgkg, up to 17.5 mg or a standard dose 0.25 mgkg, up to 25 mg of tenecteplase given intravenously. The study is designed as a parallel-group trial comparing these two dosing regimens to understand which may be more beneficial and safe for elderly stroke patients. Participants will be monitored for recovery and safety through neurological assessments using scales such as the Modified Rankin Scale and the National Institutes of Health Stroke Scale up to 90 days after treatment. Outcomes like neurological improvement, functional independence, quality of life, and any bleeding events will be closely measured. The trial will continue until December 2028, with follow-up visits planned to evaluate participants progress and overall health.

Researchers are evaluating Shuxuening injection, a multi-target neuroprotective agent, to see its effects when added to intravenous thrombolysis therapy in patients with acute ischemic stroke. This large, multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of Shuxuening injection in improving outcomes after stroke. Intravenous thrombolysis with rt-PA is the current standard treatment, but many patients still experience significant disability, so neuroprotective agents like Shuxuening may help reduce brain cell death. Participants will be randomly assigned to one of two groups one group will receive Shuxuening injection combined with intravenous thrombolysis, and the other will receive a placebo combined with intravenous thrombolysis. Both treatments involve a daily intravenous drip of 20 ml Shuxuening or placebo plus 250 ml of 0.9% sodium chloride for 10 to 14 days. The study plans to enroll 1380 patients within 6 hours of stroke onset from 50 centers across China. During the study, participants will be monitored closely with assessments including the modified Rankin Scale mRS score at 90 days to measure functional recovery, along with safety monitoring for adverse events over 90 days. Other evaluations include neurological function scores, quality of life surveys, and various safety outcomes. The trial will last for at least 90 days after treatment, with data collected on disability, recovery, and any side effects experienced.

Researchers are studying the safety and effectiveness of starting direct oral anticoagulants DOACs early versus delaying their start in adults who have had an acute ischemic stroke related to atrial fibrillation and received emergency endovascular therapy EVT. This trial is a multicenter, randomized controlled study designed to compare different timings for beginning DOAC treatment after stroke. Participants are randomly assigned to one of two groups. One group will begin taking any DOAC within 96 hours 4 days of stroke onset, while the other group will start DOAC treatment between 5 and 14 days after stroke onset. The study compares these two approaches to see which timing is safer and more effective. During the study, participants will be monitored for outcomes including recurrent ischemic stroke, symptomatic brain bleeding, and death over 90 days. Researchers will also assess other events like venous clots, heart attacks, and overall quality of life. Follow-up visits and assessments will track these health outcomes and safety measures throughout the study period, which lasts up to one year for some outcomes.

Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants DOACs early versus delayed in patients who have an acute ischemic stroke related to atrial fibrillation and develop bleeding in the brain after emergency endovascular treatment. This multicenter, open-label, randomized controlled trial focuses on the best timing to begin DOAC therapy to help manage these patients and reduce risks of complications such as recurrent stroke or bleeding. Participants will be randomly assigned to one of two groups an early anticoagulation group starting DOACs within 4 weeks of stroke onset, and a delayed anticoagulation group starting DOACs between 4 and 8 weeks after stroke onset. The study compares these two approaches to determine which timing is safer and more effective for this condition. The treatments involve any direct oral anticoagulant drug, and the trial is conducted at multiple centers with an open-label design. During the study, participants will be closely monitored for outcomes including recurrent ischemic stroke, symptomatic brain bleeding, and death over 90 days. Other assessments include measuring quality of life, hospital stay length, vascular events, and functional recovery using the modified Rankin scale. Researchers will collect data through imaging, clinical evaluations, and questionnaires. Follow-up is planned for 90 days after starting treatment to assess safety and overall health outcomes.